Abstract:Genome-wide association studies have discovered numerous common variants associated with human cancers. However, the contribution of exome-wide rare variants to cancers remains largely unexplored, especially for the protein-coding variants. The UK Biobank provides detailed cancer follow-up information linked to whole-exome sequencing (WES) for approximately 450,000 participants, offering an unprecedented opportunity to evaluate the effect of exome variation on pan-cancer. Here, we performed exome-wide association studies (ExWAS) based on single variant levels and gene levels to detect their associations across 20 primary cancer types in the discovery set (WES-300k, N = 284,456) and replication set (WES-150k, N = 143,478), separately. The ExWAS detected 143 independent variants at variant-level and 49 genes at gene-level, while nine variants and eight genes were shared across cancers. In the cross-trait meta-analysis, we identified 239 additional independent pleiotropic variants, mapping to the genes which were functional through trans-omics analyses in transcriptomics and proteomics. Further, we developed exome-wide risk scores (ERS) to identify high-risk populations based on rare variants with minor allele frequency (MAF) < 0.05. The ERS had satisfactory performance in cancer risk stratification, especially for the extremely high-risk persons (top 5% ERS) that were frequently risk allele carriers. The ERS (median C-index (IQR): 0.655 (0.636-0.667)) outperforms the traditional polygenic risk score (PRS) (median C-index (IQR): 0.585 (0.572-0.614)) for discrimination in the replication set. Our findings offer further insight into the genetic architecture of human exomes for cancer susceptibility. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported by the National Natural Science Foundation of China (82103946 to S.S., 82173620 to Y.Z., 81530088 to F.C.), National Key Research and Development Program of China (2016YFE0204900 to F.C.), Natural Science Foundation of the Jiangsu Higher Education Institutions of China (21KJB330004 to S.S.). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes UK Biobank data is available from <https://www.ukbiobank.ac.uk/>. TCGA data is available from <https://portal.gdc.cancer.gov/>. GTEx data is available from <https://www.gtexportal.org/home/>. CPTAC data is available from <https://pdc.esacinc.com/pdc/pdc>.

Discovery and reporting of clinically-relevant germline variants in advanced cancer patients assessed using whole-exome sequencing

Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results.

Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records

Assessing actionability and incidental findings of germline variants in two precision oncology trials

Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response

Exome-wide association studies discover germline mutation patterns and identify high-risk populations in human cancers

Identification and Characterization of Germline Pathogenic Variants Using Matched Tumor-Normal Next-Generation Sequencing in 7363 Pan-Cancer Patients in China

Clinical Interpretation and Implications of Whole-Genome Sequencing

Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes.

Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

Clinical application of whole-exome sequencing across clinical indications

Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer

Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing

Survey of germline variants in cancer-associated genes in young adults with colorectal cancer

Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel

Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer.

Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing